 - Patients with known bone marrow involvement will be eligible for study provided they meet the blood counts above may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions; these patients will not be evaluable for hematologic toxicity; at least 5 of every cohort of 6 patients with a solid tumor must be evaluable for hematologic toxicity for the dose escalation part of the study; if dose-limiting hematologic toxicity is observed, all subsequent patients enrolled must be evaluable for hematologic toxicity 